| Bioactivity | (S)-EB-FAPI-B2 (Compound II-11) is a precursor for radiopharmaceutical labeling, which can be combined with radionuclides to create radionuclide drug conjugates (RDCs). RDCs have the capability to specifically target biomolecules and can be used in medical imaging or therapy[1][2]. |
| CAS | 2740747-99-1 |
| Formula | C78H100N16O22S2 |
| Molar Mass | 1677.85 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Chen XY, et al. Truncated Evans blue modified fibroblast activation protein inhibitor and preparation method and application thereof. CN113582975A. 2021 November 02. [2]. Wen X, et al. Evans blue-modified radiolabeled fibroblast activation protein inhibitor as long-acting cancer therapeutics. Theranostics. 2022 Jan 1;12(1):422-433. |
(S)-EB-FAPI-B2
CAS: 2740747-99-1 F: C78H100N16O22S2 W: 1677.85
(S)-EB-FAPI-B2 (Compound II-11) is a precursor for radiopharmaceutical labeling, which can be combined with radionuclide
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.